z-logo
open-access-imgOpen Access
Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
Author(s) -
Zheng Hu,
Zan Li,
Zhicheng Ma,
Christina Curtis
Publication year - 2020
Publication title -
nature genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 18.861
H-Index - 573
eISSN - 1546-1718
pISSN - 1061-4036
DOI - 10.1038/s41588-020-0628-z
Subject(s) - biology , metastasis , cancer , primary tumor , colorectal cancer , breast cancer , cancer research , carcinogenesis , oncology , somatic evolution in cancer , exome , metastatic breast cancer , exome sequencing , medicine , mutation , gene , genetics
Metastasis is the primary cause of cancer-related deaths, but the natural history, clonal evolution and impact of treatment are poorly understood. We analyzed whole-exome sequencing (WES) data from 457 paired primary tumor and metastatic samples from 136 patients with breast, colorectal and lung cancer, including untreated (n = 99) and treated (n = 100) metastases. Treated metastases often harbored private 'driver' mutations, whereas untreated metastases did not, suggesting that treatment promotes clonal evolution. Polyclonal seeding was common in untreated lymph node metastases (n = 17 out of 29, 59%) and distant metastases (n = 20 out of 70, 29%), but less frequent in treated distant metastases (n = 9 out of 94, 10%). The low number of metastasis-private clonal mutations is consistent with early metastatic seeding, which we estimated occurred 2-4 years before diagnosis across these cancers. Furthermore, these data suggest that the natural course of metastasis is selectively relaxed relative to early tumorigenesis and that metastasis-private mutations are not drivers of cancer spread but instead associated with drug resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here